I’ve got two appearances at BIO related to the Scientific American worldView project:
On May 18th I’ll be participating in a press conference at 1pm in room A340
On May 20th I’ll be participating in a roundtable at 3:30 in Thomas B. Murphy Ballroom I, Bldg. B, Level 5.
Hope to see you all there!
The Scientific American WorldView project, where I’ve been serving as lead editorial consultant, is ramping up for its May 20th launch at BIO 2009. One of the objectives for the project was to put marketing-speak aside and objectively measure biotechnology innovation progress around the world. Going beyond gross regional measures, we compare individual countries to distill best practices, opportunities for growth, and uncover hidden gems.
Intrigued? You can hear me talk more about it on BIO’s BIOtech Now blog, and the full publication will be available at BIO 2009 in Atlanta.
I’ll be giving a talk at the Johns Hopkins Carey Business School Entrepreneurship Conference on March 21st titled “Entrepreneurship: What Not to Do.” The talk will cover cases in failed entrepreneurship in biotechnology, elucidating some of the forseeable and unforseeable factors which can lead to failure.
Hope to see some readers there. If you can’t make it, you may want to check out “Beyond the Business Plan” or Building Biotechnology, on which this latest talk is based.
I am extending my “Best Practices in Biotechnology” book series with additional books in specific niches in biotechnology commercialization. This project is based on my observation that details on many of the critically important elements in biotechnology business development – including managing global operations and regulations, communication and public relations, financial management, and using marketing to drive R&D decisions – do not receive sufficient attention in readily-accessible sources.
I am soliciting articles from industry insiders with deep experience in these areas, and welcome your proposals for chapter submissions. I feel quite strongly that a comprehensive book series covering the aforementioned topics can complement my existing books quite well and can leverage the strong textbook, trade, and library channels they have established.
This is a call for chapters on biotechnology marketing. Specifically, I am looking for case studies, best practices, guidelines, etc. in biotechnology marketing.
- Using marketing to drive R&D decisions
- Lifecycle management
- Using marketing to distinguish a firm from competitors (and, potentially, their controversies/failures)
- Driving product sales
- Novel marketing methods or challenges
- Guidelines for dealing with FDA oversight
I am also planning books on related topics such as communication, so let me know if you have any proposals for topics other than marketing.
Currently I am seeking interest in chapter contributions. The rough timeline for delivery is fall 2009, enabling publication in 2010. If you are interested in participating in this project or have any questions, please use the contact form.
I’ll be giving a talk at the Kogod School of Business on Tuesday February 24th on “Drug Development – Balancing National and Commercial Needs”. The basis of the talk is that countries need access to medicines, foreign currency, and tax revenues, while drug developers need profits (or else they will cease to exist). I’ll be covering strategies used by nations and drug companies to meet their respective needs, and describing case studies in which these needs are at odds with each other, and those in which they coexist in harmony.
Looking forward to a good discussion.
I will be opening the Business Matters for Scientists program at Johns Hopkins Carey School of Business on March 6th 2009. My focus will be providing an extensive overview of the biotechnology industry and insights on paths to entrepreneurship and business planning considerations. In addition to laying out the fundamentals for success, I will also address practical considerations in developing biotechnology companies and illustrate the diversity of entrepreneurial approaches and cases of unforeseen hurdles in biotechnology business development.
For those who cannot make it to Baltimore for the certificate program, two other options exist:
- Biotech-U.com is an online biotechnology education platform offering self-directed courses covering the scientific, legal, regulatory, political, and commercial aspects of biotechnology.
- My book, Building Biotechnology, is a comprehensive biotechnology industry primer.
For a comprehensive review of biotech happenings in 2008 and visions for 2009, check out BioProcess International’s recent article “2008 in Review.” This article features interviews with me and a number of other industry insiders about our relections on events in 2008, and projections for what the future will bring.
The January 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:
Volume 15, Issue 1
|Biotechnology commercialisation: Getting past the technology-push||PDF|
From the Classroom
Legal and Regulatory Updates
|Legal and regulatory update||PDF|
Last week I sent an update to my list of biotech educators about the availability of instructor resources for Building Biotechnology. I’m starting to see interest among educators who I didn’t email, so I ‘m posting a follow-up here to spread the word.
The instructor resources are free for qualified educators and include figures and tables from the text, and sample lectures. Slide decks based on each chapter are also available for a fee, and a quiz bank will be posted shortly.
The instructor resources can be accessed at here, more information on Building Biotechnology is available at here, and the list of schools which have adopted the text is here
I’m working on an International Biotechnology ranking and comparison for a well-known publication, and am looking for data sets comparing biotechnology activities in different countries as well as interesting anecdotes about successes/failures/challenges encountered in developing biotechnology in different countries as well between countries. If you’ve got comparative data sets or interesting anecdotes, please drop me a line.